EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Beta-Blockers Lower First Decompensation in Patients With Cirrhosis and Enduring Portal Hypertension After Etiological Treatment

Laura Turco, Madalina-Gabriela Taru, Giovanni Vitale, Horia Stefanescu, Federica Mirici Cappa, Sonia Berardi, Anna Baldan, Roberto Di Donato, Paolo Pianta, Vittoria Vero, Luca Vizioli, Lucia Maria Procopciuc und 3 weitere

Clinical Gastroenterology and Hepatology · 2025

DOI: 10.1016/j.cgh.2024.08.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Laura Turco und 14 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Unit for the Treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Hypertension, Portal, Adrenergic beta-Antagonists, Liver Cirrhosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Non-selective beta-blockers (NSBBs) can lower the risk of first decompensation in patients with cirrhosis and clinically significant portal hypertension (CSPH) (identified by a hepatic venous pressure gradient ≥10 mm Hg) with active etiology. Our aim was to examine the effect of NSBBs on first decompensation occurrence in patients with cirrhosis and enduring CSPH after etiological treatment. METHODS: Patients with compensated cirrhosis and clinical evidence of CSPH (gastroesophageal varices [GEVs] and/or spontaneous portosystemic collaterals [SPSSs]) after 2 years from etiological treatment. The primary endpoint was first decompensation (occurrence of variceal bleeding, ascites, or hepatic encephalopathy) in patients on NSBBs vs off NSBBs. RESULTS: The final cohort included 406 patients. Baseline characteristics of patients on NSBBs (n = 187) and off NSBBs (n = 219) were comparable, except for signs of portal hypertension that were more pronounced in the on-NSBBs group. During a mean follow-up of 32 months, 127 (31%) patients decompensated, with ascites being the most common (77%) decompensating event. Decompensation rates were lower in patients on NSBBs (16% vs 44%; P < .0001). The benefit of NSBBs on decompensation was maintained in patients with small GEVs (17% vs 43%; P < .0001), in those with spontaneous portosystemic shunt only (8% vs 43%; P = .003), and in each different etiology, including hepatitis C virus-cured cirrhosis (9% vs 32%; P < .0001). At Cox regression analysis, hemoglobin, Child-Pugh, Model for End-Stage Liver Disease-Sodium, diabetes at baseline, and previous bacterial infections were independent predictors of decompensation, while NSBBs use had a protective effect (hazard ratio, 0.32; 95% confidence interval, 0.20-0.49; P < .0001). NSBBs use significantly reduced bacterial infection rates (hazard ratio, 0.36; 95% confidence interval, 0.22-0.58; P < .0001). CONCLUSION: NSBBs decrease the risk of first decompensation in patients with cirrhosis and enduring CSPH after etiological treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PortalAdrenergic beta-AntagonistsLiver CirrhosisHumansMaleFemaleMiddle AgedAgedTreatment OutcomeEsophageal and Gastric VaricesAscitesAdultGastrointestinal HemorrhageHepatic Encephalopathy

Stichwörter der Autor:innen

AscitesCarvedilolHepatic DecompensationNonselective Beta-Blockers

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Internal Medicine Unit for the Treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Hepatology Department, Regional Institute of Gastroenterology and Hepatology Octavian Fodor, Cluj-Napoca, Romania; Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; Division…
  • Hepatology Department, Regional Institute of Gastroenterology and Hepatology Octavian Fodor, Cluj-Napoca, Romania.
  • Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Hepatology Department, Regional Institute of Gastroenterology and Hepatology Octavian Fodor, Cluj-Napoca, Romania; Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna,…

Zitieren

APA

Turco, L., Taru, M. G., Vitale, G., Stefanescu, H., Mirici Cappa, F., Berardi, S., Baldan, A., Di Donato, R., Pianta, P., Vero, V., Vizioli, L., Procopciuc, L. M., Procopet, B., Morelli, M. C., & Piscaglia, F. (2025). Beta-Blockers Lower First Decompensation in Patients With Cirrhosis and Enduring Portal Hypertension After Etiological Treatment. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.08.012

Vancouver

Turco L, Taru MG, Vitale G, Stefanescu H, Mirici Cappa F, Berardi S, et al. Beta-Blockers Lower First Decompensation in Patients With Cirrhosis and Enduring Portal Hypertension After Etiological Treatment. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.08.012

BibTeX
@article{Turco2025,
  author = {Turco, Laura and Taru, Madalina-Gabriela and Vitale, Giovanni and Stefanescu, Horia and Mirici Cappa, Federica and Berardi, Sonia and Baldan, Anna and Di Donato, Roberto and Pianta, Paolo and Vero, Vittoria and Vizioli, Luca and Procopciuc, Lucia Maria and Procopet, Bogdan and Morelli, Maria Cristina and Piscaglia, Fabio},
  title = {Beta-Blockers Lower First Decompensation in Patients With Cirrhosis and Enduring Portal Hypertension After Etiological Treatment},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1016/j.cgh.2024.08.012}
}
Kostenlos starten →